Clinical Trial Update: A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children [Phase 3]

View source ↗

Summary

Phase 3 trial of the 13-valent pneumococcal conjugate vaccine in healthy Chinese infants and young children has completed and results were posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Infections, Pneumococcal Conjugate Vaccine | Phase 3 | Status: COMPLETED | Results posted: 2024-04-26